Kaleido Biosciences, Inc. Common Stock
KLDO
KLDO was delisted on the 14th of April, 2022.
71 hedge funds and large institutions have $190M invested in Kaleido Biosciences, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 10 closing their positions.
126% more call options, than puts
Call options by funds: $335K | Put options by funds: $148K
57% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 14
0% more funds holding
Funds holding: 71 → 71 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
26% less capital invested
Capital invested by funds: $258M → $190M (-$68.2M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$620K |
| 2 |
State Street
Boston,
Massachusetts
|
+$421K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$219K |
| 4 |
State Board of Administration of Florida Retirement System
Tallahassee,
Florida
|
+$211K |
| 5 |
Renaissance Technologies
New York
|
+$185K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Charles Schwab
San Francisco,
California
|
-$564K |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
-$410K |
| 3 |
Two Sigma Advisers
New York
|
-$342K |
| 4 |
ED
Exane Derivatives
Paris,
France
|
-$157K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$144K |
KLDO Hedge Fund Activity: Q3 2021 in Review
71 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Kaleido Biosciences, Inc. Common Stock (KLDO) for Q3 2021, worth a combined $190M — down 26% from $258M a quarter earlier.
Fund positioning in KLDO was balanced in Q3 2021: 10 funds opened new positions, 10 closed out, 22 added to existing stakes and 14 trimmed.
The largest buyer was Ikarian Capital, opening a new position worth an estimated $620K. The largest seller was Charles Schwab, cutting an estimated $564K.
- 71 institutional investors held Kaleido Biosciences, Inc. Common Stock (KLDO) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $190M of Kaleido Biosciences, Inc. Common Stock stock for Q3 2021, down 26% quarter-over-quarter.
- 10 funds opened new Kaleido Biosciences, Inc. Common Stock positions in Q3 2021 and 10 closed out, a net change of 0 holders.
- The largest Kaleido Biosciences, Inc. Common Stock buyer in Q3 2021 was Ikarian Capital, an estimated $620K added.
- The largest Kaleido Biosciences, Inc. Common Stock seller in Q3 2021 was Charles Schwab, an estimated $564K sold.
Based on aggregated 13F filings for Q3 2021.